# Assessment of Rituximab Therapeutic Response Versus Conventional Treatment

> **NCT05553496** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Ain Shams University** · enrollment: 40 (estimated)

## Conditions studied

- Pharmacological Action

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05553496
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-25
- **Primary completion:** 2023-04-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05553496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05553496, "Assessment of Rituximab Therapeutic Response Versus Conventional Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05553496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*